Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats.
BACKGROUND
Acute systemic ethanol administration is known to elevate plasma and cerebral levels of neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one (3alpha, 5alpha-THP; allopregnanolone) to a concentration sufficient to potentiate GABA(A) receptors. We have earlier demonstrated that 3alpha, 5alpha-THP mediates the antidepressant-like effect of ethanol in Porsolt forced swim test.


OBJECTIVE
The aim of the present study is to explain the relationship between endogenous GABAergic neurosteroids and anxiolytic effect of ethanol in Sprague-Dawley rats.


METHODS
The mediation of 3alpha, 5alpha-THP in the anti-anxiety effect of ethanol was assessed by pharmacological interactions of ethanol with various endogenous neurosteroidal modulators and using simulated physiological conditions of altered neurosteroid content in elevated plus maze (EPM) test.


RESULTS
Pretreatment of 3alpha, 5alpha-THP (0.5-2.5 mug/rat, i.c.v.) or neurosteroidogenic agents such as 3alpha, 5alpha-THP precursor progesterone (5 or 10 mg/kg, i.p.), 11-beta hydroxylase inhibitor metyrapone (50 or 100 mg/kg, i.p.) or the GABA(A) receptor agonist muscimol (25 ng/rat, i.c.v.) significantly potentiated the anti-anxiety effect of ethanol (1 g/kg, i.p.). On the other hand, the GABAergic antagonistic neurosteroid dehydroepiandrosterone sulphate (DHEAS) (1 mg/kg, i.p.), the GABA(A) receptor blocker bicuculline (1 mg/kg, i.p.), the 5alpha-reductase inhibitor finasteride (50 x 2 mg/kg, s.c.) or the mitochondrial diazepam binding inhibitory receptor antagonist PK11195 (1 mg/kg, i.p.) reduced ethanol-induced preference of time spent and number of entries into open arms. Anti-anxiety effect of ethanol was abolished in adrenalectomized (ADX) rats as compared to sham-operated control. This ADX-induced blockade was restored by prior systemic injection of progesterone, signifying the contribution of peripheral steroidogenesis in ethanol anxiolysis. Socially isolated animals known to exhibit decreased brain 3alpha, 5alpha-THP and GABA(A) receptor functions displayed reduced sensitivity to the effects of ethanol and 3alpha, 5alpha-THP in EPM test.


CONCLUSIONS
Our results demonstrated the contributory role of neuroactive steroid 3alpha, 5alpha-THP in the anti-anxiety effect of ethanol. It is speculated that ethanol-induced modulation of endogenous GABAergic neurosteroids, especially 3alpha, 5alpha-THP, might be crucial pertinent to the etiology of 'trait' anxiety (tension reduction) and ethanol abuse.
Hirani
Khemraj
K
Department of Pharmaceutical Sciences, Nagpur University Campus, Nagpur, 440 033, Maharashtra, India.
Sharma
Ajay N
AN
Jain
Nishant S
NS
Ugale
Rajesh R
RR
Chopde
Chandrabhan T
CT
D000315:Adrenalectomy; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D000431:Ethanol / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D011280:Pregnanolone / Q000502:physiology*; D011374:Progesterone / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000187:drug effects; D012934:Social Isolation
D014151:Anti-Anxiety Agents; D011963:Receptors, GABA-A; D000431:Ethanol; D011374:Progesterone; D011280:Pregnanolone
World J Biol Psychiatry. 2002 Apr;3(2):87-95
12479081
J Abnorm Psychol. 1976 Dec;85(6):601-6
993457
Trends Pharmacol Sci. 1995 Sep;16(9):295-303
7482994
Synapse. 1995 Nov;21(3):189-274
8578436
Neuropharmacology. 2002 Dec;43(8):1339-50
12527484
Neuroreport. 1994 Oct 27;5(16):2093-6
7865753
Alcohol Health Res World. 1997;21(2):144-8
15704351
Science. 1980 Aug 8;209(4457):708-10
7394531
Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):267-82
9303562
Alcohol Clin Exp Res. 1998 Aug;22(5):1106-12
9726282
J Endocrinol. 1996 Sep;150 Suppl:S221-39
8943804
Pharmacol Ther. 2004 Feb;101(2):91-112
14761701
Pharmacol Biochem Behav. 1986 Jul;25(1):233-48
2875470
J Pharmacol Exp Ther. 1995 Dec;275(3):1590-6
8531133
Pharmacol Biochem Behav. 2002 May;72(1-2):449-55
11900819
Life Sci. 1983 Apr 18;32(16):1839-47
6300588
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2849-54
11226329
Eur J Pharmacol. 2004 Jan 26;484(2-3):241-7
14744609
Brain Res. 1996 Jul 8;726(1-2):1-10
8836539
J Neurosci Methods. 1985 Aug;14(3):149-67
2864480
Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217
10209232
J Clin Psychol. 1978 Apr;34(2):417-8
681517
Brain Res Brain Res Rev. 2001 Nov;37(1-3):110-5
11744079
Neuropsychopharmacology. 2004 Sep;29(9):1597-609
15100702
Alcohol Clin Exp Res. 1998 Dec;22(9):2055-61
9884151
Psychopharmacology (Berl). 1987;92 (2):180-5
3110839
J Soc Biol. 1999;193(3):293-8
10542960
Pharmacol Biochem Behav. 2003 Dec;76(3-4):417-23
14643840
J Neurochem. 2002 Dec;83(5):1103-9
12437581
J Comp Neurol. 1999 Mar 22;405(4):529-42
10098943
Pharmacol Biochem Behav. 1997 Feb;56(2):261-4
9050083
J Pharmacol Exp Ther. 1996 Apr;277(1):484-90
8613958
Int Rev Neurobiol. 2001;46:349-77
11599306
Fed Proc. 1981 May 15;40(7):2056-64
7194802
Alcohol. 2000 Jan;20(1):69-74
10680719
FASEB J. 1992 Mar;6(6):2311-22
1347506
J Pharmacol Exp Ther. 1991 Dec;259(3):1288-93
1762076
Nature. 1998 Oct 15;395(6703):652-3
9790185
Psychopharmacology (Berl). 1988;96(1):67-72
2906444
Psychopharmacology (Berl). 2000 Jun;150(3):300-10
10923758
Alcohol Clin Exp Res. 2002 Nov;26(11):1747-51
12436065
Pharmacol Biochem Behav. 2003 Dec;76(3-4):451-62
14643844
Brain Res Brain Res Rev. 2001 Nov;37(1-3):98-109
11744078
Pharmacol Biochem Behav. 1993 Jun;45(2):423-8
8392205
J Neurosci. 2000 Mar 1;20(5):1982-9
10684899
Pharmacol Biochem Behav. 1998 Jan;59(1):221-32
9443559
J Pharmacol Exp Ther. 1998 Feb;284(2):768-76
9454826
Psychopharmacology (Berl). 2000 Jul;151(1):64-71
10958118
Psychopharmacology (Berl). 1995 Mar;118(1):65-71
7597124
Alcohol. 1992 Nov-Dec;9(6):529-33
1472310
Neuroscience. 1998 Aug;85(3):979-88
9639289
Psychoneuroendocrinology. 1991;16(6):517-23
1667336
Psychopharmacology (Berl). 2002 Aug;162(4):438-47
12172699
Psychoneuroendocrinology. 1996 Apr;21(3):277-86
8817726
Adv Biochem Psychopharmacol. 1995;48:57-74
7653326
Psychopharmacology (Berl). 1985;86(1-2):170-4
3927353
Psychopharmacol Bull. 1987;23(3):452-7
3324152
Psychopharmacology (Berl). 1996 Dec;128(4):380-97
8986009
Alcohol Res Health. 1999;23(4):263-71
10890823
Am J Psychiatry. 1994 Dec;151(12):1723-34
7977877
Brain Res. 1988 Jul 12;455(2):377-80
2900060
Psychopharmacology (Berl). 1995 Apr;118(3):316-23
7617825
J Pharmacol Exp Ther. 1994 Oct;271(1):164-70
7965710
Pharmacol Biochem Behav. 1995 Oct;52(2):297-303
8577794
Neuropharmacology. 1999 Jul;38(7):955-63
10428414
Alcohol. 2002 Jan;26(1):55-9
11958948
Psychopharmacology (Berl). 1998 Apr;136(3):291-8
9566815
Behav Pharmacol. 1997 Nov;8(6-7):541-8
9832968
Alcohol Alcohol. 1989;24(5):447-51
2818752
Eur J Pharmacol. 1999 Nov 19;384(2-3):R1-2
10611449
Brain Res. 2003 Aug 8;980(2):255-65
12867266
J Pharmacol Exp Ther. 1999 Feb;288(2):679-84
9918575
Biol Psychiatry. 1998 Nov 1;44(9):912-4
9807647
Brain Res. 1991 Oct 4;561(1):157-61
1686744
Drugs Today (Barc). 2002 Jul;38(7):465-85
12582464
Proc Natl Acad Sci U S A. 1991 May 15;88(10):4553-7
1852011
Neuron. 1993 Sep;11(3):523-30
8398145
Ann N Y Acad Sci. 1995 Dec 29;771:257-72
8597405
Neuroendocrinology. 1996 Feb;63(2):166-72
9053781
Psychopharmacology (Berl). 2002 May;161(2):120-8
11981591
J Neurosci. 2002 Dec 15;22(24):10613-20
12486153
Neuropharmacology. 2000 Sep;39(12 ):2448-56
10974329
Psychiatr Dev. 1987 Winter;5(4):377-92
2832841
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3220-3
8159728